# Phase 1A Study of the Safety of KSP/QRH Dimer

> **NCT03643068** · PHASE1 · COMPLETED · sponsor: **University of Michigan** · enrollment: 26 (actual)

## Conditions studied

- Healthy Adults

## Interventions

- **DRUG:** KSP-QRH-E3-IRDye800 (Peptide 919288G), 0.6 mg
- **DRUG:** KSP-QRH-E3-IRDye800 (Peptide 919288G), 1.8 mg

## Key facts

- **NCT ID:** NCT03643068
- **Lead sponsor:** University of Michigan
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-08-22
- **Primary completion:** 2018-10-27
- **Final completion:** 2018-10-27
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2018-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03643068

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03643068, "Phase 1A Study of the Safety of KSP/QRH Dimer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03643068. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*